JP2023010979A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023010979A5 JP2023010979A5 JP2022187561A JP2022187561A JP2023010979A5 JP 2023010979 A5 JP2023010979 A5 JP 2023010979A5 JP 2022187561 A JP2022187561 A JP 2022187561A JP 2022187561 A JP2022187561 A JP 2022187561A JP 2023010979 A5 JP2023010979 A5 JP 2023010979A5
- Authority
- JP
- Japan
- Prior art keywords
- group
- ala
- core sequence
- seq
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims 29
- LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 claims 14
- 206010061218 Inflammation Diseases 0.000 claims 11
- 230000004054 inflammatory process Effects 0.000 claims 11
- 125000000539 amino acid group Chemical group 0.000 claims 8
- QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 claims 7
- UBXUDSPYIGPGGP-UHFFFAOYSA-N 2-azaniumyl-2-phenylbutanoate Chemical compound CCC(N)(C(O)=O)C1=CC=CC=C1 UBXUDSPYIGPGGP-UHFFFAOYSA-N 0.000 claims 7
- OFYAYGJCPXRNBL-UHFFFAOYSA-N 2-azaniumyl-3-naphthalen-1-ylpropanoate Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CC=CC2=C1 OFYAYGJCPXRNBL-UHFFFAOYSA-N 0.000 claims 7
- QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 claims 7
- UQBOJOOOTLPNST-UHFFFAOYSA-N Dehydroalanine Chemical compound NC(=C)C(O)=O UQBOJOOOTLPNST-UHFFFAOYSA-N 0.000 claims 7
- -1 β-cyclohexyl-Ala Chemical compound 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 238000007920 subcutaneous administration Methods 0.000 claims 3
- 230000000699 topical effect Effects 0.000 claims 3
- 206010028116 Mucosal inflammation Diseases 0.000 claims 2
- 201000010927 Mucositis Diseases 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 208000036142 Viral infection Diseases 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 208000019622 heart disease Diseases 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000026731 phosphorylation Effects 0.000 claims 1
- 238000006366 phosphorylation reaction Methods 0.000 claims 1
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 claims 1
- 230000009385 viral infection Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462055982P | 2014-09-26 | 2014-09-26 | |
| US62/055,982 | 2014-09-26 | ||
| JP2021036502A JP7184946B2 (ja) | 2014-09-26 | 2021-03-08 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021036502A Division JP7184946B2 (ja) | 2014-09-26 | 2021-03-08 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023010979A JP2023010979A (ja) | 2023-01-20 |
| JP2023010979A5 true JP2023010979A5 (https=) | 2023-05-29 |
Family
ID=55582262
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516948A Active JP6851965B2 (ja) | 2014-09-26 | 2015-09-25 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
| JP2021036502A Active JP7184946B2 (ja) | 2014-09-26 | 2021-03-08 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
| JP2022187561A Pending JP2023010979A (ja) | 2014-09-26 | 2022-11-24 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
Family Applications Before (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017516948A Active JP6851965B2 (ja) | 2014-09-26 | 2015-09-25 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
| JP2021036502A Active JP7184946B2 (ja) | 2014-09-26 | 2021-03-08 | 疾患及び障害の治療のためのｎｆカッパｂ活性の阻害剤 |
Country Status (7)
| Country | Link |
|---|---|
| US (5) | US10030048B2 (https=) |
| EP (1) | EP3197474B1 (https=) |
| JP (3) | JP6851965B2 (https=) |
| CN (2) | CN114432423A (https=) |
| AU (2) | AU2015320341B2 (https=) |
| CA (1) | CA2999711A1 (https=) |
| WO (1) | WO2016049580A2 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3197474B1 (en) | 2014-09-26 | 2023-06-07 | Rajendra Sahai Bhatnagar | Inhibitors of nf kappa-b activity for treatment of diseases and disorders |
| US9943566B2 (en) | 2016-03-16 | 2018-04-17 | Geoffrey Brooks Consultants, Llc | NF-κB inhibitor composition for skin health |
| CA3191058A1 (en) * | 2020-08-28 | 2022-03-03 | Rajendra Sahai Bhatnagar | Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU215581B (hu) * | 1989-07-06 | 1999-01-28 | Regents Of The University Of California | Eljárás fibroblaszt növekedési faktor receptorok előállítására és terápiás alkalmazására |
| US5635482A (en) | 1989-08-14 | 1997-06-03 | The Regents Of The University Of California | Synthetic compounds and compositions with enhanced cell binding |
| US20030077825A1 (en) | 1994-07-22 | 2003-04-24 | Bhatnagar Rajendra S. | Structures useful for bone engineering and methods |
| US5354736A (en) | 1989-08-14 | 1994-10-11 | Regents Of The University Of California | Synthetic compounds and compositions with enhanced cell binding |
| US5674848A (en) | 1989-08-14 | 1997-10-07 | The Regents Of The University Of California | Bioreactor compositions with enhanced cell binding |
| WO1991002537A1 (en) | 1989-08-14 | 1991-03-07 | The Regents Of The University Of California | Synthetic peptides that enhance cell binding |
| WO1995016709A2 (en) * | 1993-12-13 | 1995-06-22 | Biogen, Inc. | Anti-mullerian hormone receptor polypeptides and antibodies thereto |
| US5661127A (en) | 1995-05-01 | 1997-08-26 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
| US6638912B2 (en) | 1995-05-01 | 2003-10-28 | The Regents Of The University Of California | Peptide compositions mimicking TGF-β activity |
| US5780436A (en) | 1995-05-01 | 1998-07-14 | The Regents Of The University Of California | Peptide compositions with growth factor-like activity |
| WO1998009620A1 (en) * | 1996-09-05 | 1998-03-12 | Research Development Foundation | INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN |
| US6197586B1 (en) | 1997-12-12 | 2001-03-06 | The Regents Of The University Of California | Chondrocyte-like cells useful for tissue engineering and methods |
| US6864355B1 (en) | 2000-05-02 | 2005-03-08 | Yale University | Inhibition of NF-κB activation by blockade of IKKβ-NEMO interactions at the NEMO binding domain |
| DE19951360A1 (de) * | 1999-10-26 | 2001-05-03 | Aventis Pharma Gmbh | Substituierte Indole |
| WO2001082773A2 (en) | 2000-04-28 | 2001-11-08 | The Regents Of The University Of California | Structures useful for bone engineering and methods |
| US6509318B1 (en) * | 2000-09-29 | 2003-01-21 | The Regents Of The University Of California | TGF-B inhibitors and methods |
| AUPR279101A0 (en) * | 2001-01-30 | 2001-02-22 | Cytopia Pty Ltd | Protein kinase signalling |
| PT1678209E (pt) * | 2003-10-07 | 2011-06-30 | Yeda Res & Dev | Anticorpos para a nik, a sua preparação e a sua utilização |
| EP1869206A4 (en) * | 2005-03-02 | 2011-08-10 | Einstein Coll Med | ENZYME SENSORS WITH ENVIRONMENTAL SENSITIVE OR FLUORESCENT LABELS AND APPLICATIONS THEREOF |
| WO2006133027A2 (en) | 2005-06-03 | 2006-12-14 | Bhatnagar Rajendra S | Methods for immobilizing molecules on surfaces |
| US20060293228A1 (en) | 2005-06-24 | 2006-12-28 | Bhatnagar Rajendra S | Therapeutic compositions and methods using transforming growth factor-beta mimics |
| US20060293227A1 (en) | 2005-06-24 | 2006-12-28 | Bhatnagar Rajendra S | Cosmetic compositions and methods using transforming growth factor-beta mimics |
| CA2722754A1 (en) | 2007-04-27 | 2009-01-29 | The University Of Toledo | Modified plasminogen activator inhibitor type-1 molecule and methods based thereon |
| WO2009013753A1 (en) * | 2007-07-24 | 2009-01-29 | Thrombotech Ltd. | Peptides derived from plasminogen activator inhibitor-1 and uses thereof |
| JP2010536341A (ja) * | 2007-08-15 | 2010-12-02 | アムニクス， インコーポレイテッド | 生物学的に活性なポリペプチドの特性を改変するための組成物および方法 |
| EP2124060A1 (en) * | 2008-05-23 | 2009-11-25 | ETH Zurich | Method for high throughput peptide/protein assay generation and assays generated therewith |
| WO2009152610A1 (en) | 2008-06-20 | 2009-12-23 | The Royal Institution For The Advancement Of Learning/Mcgill University | Interleukin-2/soluble tgf-beta type ii receptor b conjugates and methods and uses thereof |
| WO2010051064A1 (en) * | 2008-10-30 | 2010-05-06 | The Trustees Of Columbia University In The City Of New York | COMPOUNDS THAT INHIBIT NFκB ACTIVITY |
| AU2010253834B2 (en) * | 2009-05-27 | 2013-12-19 | Dana-Farber Cancer Institute, Inc. | Inhibition 0f inflammation using antagonists of MUC1 |
| WO2011087768A1 (en) * | 2009-12-22 | 2011-07-21 | Stryker Corporation | Bmp-7 variants with reduced immunogenicity |
| JP2013176368A (ja) * | 2012-02-28 | 2013-09-09 | Oncotherapy Science Ltd | Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン |
| CN103223175B (zh) * | 2013-05-23 | 2015-07-22 | 中国人民解放军第三军医大学第三附属医院 | 抗瘢痕和组织纤维化寡聚双链核苷酸药物及其应用 |
| US20160000682A1 (en) | 2014-07-02 | 2016-01-07 | Geoffrey Brooks Consultants Llc | Peptide-Based Compositions and Methods of Use |
| EP3197474B1 (en) | 2014-09-26 | 2023-06-07 | Rajendra Sahai Bhatnagar | Inhibitors of nf kappa-b activity for treatment of diseases and disorders |
| US9943566B2 (en) | 2016-03-16 | 2018-04-17 | Geoffrey Brooks Consultants, Llc | NF-κB inhibitor composition for skin health |
| DE202018003082U1 (de) | 2018-07-03 | 2019-10-07 | Ergon International Gmbh | Fahrradsattel |
| CA3191058A1 (en) | 2020-08-28 | 2022-03-03 | Rajendra Sahai Bhatnagar | Peptide inhibitors of nf kappa b and use thereof in treatment of covid-19 and inflammatory diseases |
-
2015
- 2015-09-25 EP EP15844064.4A patent/EP3197474B1/en active Active
- 2015-09-25 US US14/866,040 patent/US10030048B2/en active Active
- 2015-09-25 CA CA2999711A patent/CA2999711A1/en active Pending
- 2015-09-25 CN CN202111512016.7A patent/CN114432423A/zh active Pending
- 2015-09-25 CN CN201580064157.3A patent/CN106999535B/zh active Active
- 2015-09-25 AU AU2015320341A patent/AU2015320341B2/en active Active
- 2015-09-25 JP JP2017516948A patent/JP6851965B2/ja active Active
- 2015-09-25 WO PCT/US2015/052467 patent/WO2016049580A2/en not_active Ceased
-
2018
- 2018-05-17 US US15/982,837 patent/US11174286B2/en active Active
-
2021
- 2021-03-08 JP JP2021036502A patent/JP7184946B2/ja active Active
- 2021-08-25 AU AU2021221579A patent/AU2021221579B2/en active Active
- 2021-10-19 US US17/505,544 patent/US11773135B2/en active Active
-
2022
- 2022-11-24 JP JP2022187561A patent/JP2023010979A/ja active Pending
-
2023
- 2023-08-22 US US18/453,807 patent/US12325760B2/en active Active
-
2025
- 2025-05-13 US US19/206,572 patent/US20260015386A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023010979A5 (https=) | ||
| JP2021091728A5 (https=) | ||
| JP2020073481A5 (https=) | ||
| EP0235205B1 (en) | Peptide analogues of mammalian insulin-like growth factor-1 | |
| US5470828A (en) | Peptide analogs of insulin-like growth factor II | |
| US20150232527A1 (en) | Glucagon-like peptide-1 analogue monomer and dimer, preparation method therefor and application thereof | |
| EP0536741B1 (en) | Cyclic VIP analogs | |
| JP2002504112A (ja) | 上部胃腸管の安全性を高めるためのフィルムコーティング錠 | |
| JP2002511385A5 (https=) | ||
| CN102643339B (zh) | 一种glp-1类似物、制备方法及其应用 | |
| WO1990009162A2 (en) | Anaphylatoxin-receptor ligands | |
| JP2025166240A5 (https=) | ||
| JPH0273100A (ja) | 医薬用化合物 | |
| JP3250804B2 (ja) | 治療用ペプチド | |
| IE914398A1 (en) | Hexa- and heptapeptide anaphylatoxin-receptor ligands | |
| CN1917898B (zh) | 用于治疗间质肺部感染的血管活性肠肽的生物活性物质 | |
| HUT61036A (en) | Process for producing new polypeptides capable of linking to lipopolysaccharides and pharmaceutical compositions comprising same as active ingredients | |
| EP0564533A1 (en) | Modified penta- and hexapeptide anaphylatoxin receptor ligands | |
| DE69430295T2 (de) | Pulver zur nasalen Verabreichung peptidischer oder proteinischer Arzneistoffe | |
| PL165133B1 (pl) | Sposób wytwarzania nowych peptydów PL PL PL PL PL PL | |
| Deunas et al. | Use of interferon-α in laryngeal papillomatosis: eight years of the Cuban national programme | |
| HU199879B (en) | Process for producing hexapeptides and pharmaceutical compositions comprising same as active ingredient | |
| JP2018500274A5 (https=) | ||
| JP2022518527A5 (https=) | ||
| JPS60161999A (ja) | ペプチド |